论文信息 - FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing - 字舞流文

FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing

A. Shamas-Din | L. Kay | S. Trudel | S. Climie | R. Al-awar | R. Hurren | A. Schimmer | Z. Wang | A. Aman | A. Ruschak | E. Undzys | B. Press | X. Wang | A. Nachman | C. Griffin | P. Dove | Z. Li | Y. J. Oh | D. O'Neill | M. Slassi | R. Al-Awar